Bristol Myers Squibb reports lung cancer results for Bristol Myers Squibb stock

Published on 10/26/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PANKU-Lung01 showed 11.1 versus 5.7 months. Bristol Myers Squibb stock costs EUR 55.12 on October 26, 2026.

Pipeline results and upcoming dates

PANKU-Lung01 showed median progression-free survival of 11.1 months versus 5.7 months on October 26, 2026.
Second-quarter 2026 revenue reached USD 12.97 billion and rose 5.70 percent year over year.
Bristol Myers Squibb stock trades at EUR 55.12 at 11:18 a.m. CEST at Lang & Schwarz on October 26, 2026.
Third-quarter 2026 results are scheduled for October 29, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) reported median progression-free survival of 11.1 months with izalontamab brengitecan versus 5.7 months with platinum-based chemotherapy in the Phase 3 PANKU-Lung01 study. The company and SystImmune announced the interim results on October 26, 2026, according to Bristol Myers Squibb.

Trial data add to oncology pipeline

The trial enrolled 216 patients in the izalontamab brengitecan group and 206 in the chemotherapy group. The progression-risk hazard ratio was 0.40, with a 95 percent confidence interval of 0.31 to 0.51 and a p-value below 0.0001, according to the release.

The result follows another pipeline update on October 25, 2026, when Bristol Myers Squibb and BioNTech reported a 36.70 percent objective response rate and median progression-free survival of 6.90 months in a Phase 2 lung cancer study.

What does the pipeline mean for revenue?

The near-term test remains commercial execution. Bristol Myers Squibb generated USD 12.97 billion in second-quarter 2026 revenue, up 5.70 percent from the prior-year quarter, while diluted earnings per share were USD 1.62. The financial figures come from the standardized quarterly statement, while the reported comparison was also carried by MarketBeat.

Three dated pipeline events

On October 8, 2026, Bristol Myers Squibb reported median progression-free survival of 42 months versus 20 months in the Phase 3 EXCALIBER-RRMM study, as reported by Stock Titan. On October 25, 2026, the company reported Pumitamig data with a 36.70 percent response rate. On October 26, 2026, PANKU-Lung01 showed 11.1 months versus 5.7 months.

Upcoming dates carry the next test

The European Society for Medical Oncology Congress runs through October 27, 2026, and Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026, according to its corporate release.

Stock quote before the results

Bristol Myers Squibb was trading at EUR 55.12 at Lang & Schwarz on October 26, 2026 at 11:18 a.m. CEST. The company is listed on the NYSE under the ticker BMY and operates in the healthcare sector.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.